JP7367910B2 - がんの処置 - Google Patents

がんの処置 Download PDF

Info

Publication number
JP7367910B2
JP7367910B2 JP2018563084A JP2018563084A JP7367910B2 JP 7367910 B2 JP7367910 B2 JP 7367910B2 JP 2018563084 A JP2018563084 A JP 2018563084A JP 2018563084 A JP2018563084 A JP 2018563084A JP 7367910 B2 JP7367910 B2 JP 7367910B2
Authority
JP
Japan
Prior art keywords
cancer
treatment
protide
stem cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521971A (ja
JP2019521971A5 (cg-RX-API-DMAC7.html
Inventor
グリフィス ヒュー
ペッパー クリス
マクギガン クリス
Original Assignee
ニューカナ パブリック リミテッド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューカナ パブリック リミテッド カンパニー filed Critical ニューカナ パブリック リミテッド カンパニー
Publication of JP2019521971A publication Critical patent/JP2019521971A/ja
Publication of JP2019521971A5 publication Critical patent/JP2019521971A5/ja
Priority to JP2022020897A priority Critical patent/JP2022051965A/ja
Application granted granted Critical
Publication of JP7367910B2 publication Critical patent/JP7367910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018563084A 2016-06-01 2017-05-31 がんの処置 Active JP7367910B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022020897A JP2022051965A (ja) 2016-06-01 2022-02-15 がんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments
GB1609600.0 2016-06-01
PCT/GB2017/051560 WO2017207993A1 (en) 2016-06-01 2017-05-31 Cancer treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022020897A Division JP2022051965A (ja) 2016-06-01 2022-02-15 がんの処置

Publications (3)

Publication Number Publication Date
JP2019521971A JP2019521971A (ja) 2019-08-08
JP2019521971A5 JP2019521971A5 (cg-RX-API-DMAC7.html) 2020-06-25
JP7367910B2 true JP7367910B2 (ja) 2023-10-24

Family

ID=56410849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563084A Active JP7367910B2 (ja) 2016-06-01 2017-05-31 がんの処置
JP2022020897A Pending JP2022051965A (ja) 2016-06-01 2022-02-15 がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022020897A Pending JP2022051965A (ja) 2016-06-01 2022-02-15 がんの処置

Country Status (19)

Country Link
US (2) US11400107B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463384A1 (cg-RX-API-DMAC7.html)
JP (2) JP7367910B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190011770A (cg-RX-API-DMAC7.html)
CN (1) CN109562119A (cg-RX-API-DMAC7.html)
AU (1) AU2017273124B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074981A2 (cg-RX-API-DMAC7.html)
CA (1) CA3025442C (cg-RX-API-DMAC7.html)
CL (2) CL2018003443A1 (cg-RX-API-DMAC7.html)
EA (1) EA038030B1 (cg-RX-API-DMAC7.html)
GB (1) GB201609600D0 (cg-RX-API-DMAC7.html)
IL (1) IL263123B (cg-RX-API-DMAC7.html)
MA (1) MA45129A (cg-RX-API-DMAC7.html)
MX (1) MX2018014840A (cg-RX-API-DMAC7.html)
MY (1) MY199129A (cg-RX-API-DMAC7.html)
PH (1) PH12018502491A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810196RA (cg-RX-API-DMAC7.html)
WO (1) WO2017207993A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807811B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
LT3224268T (lt) 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN113164773B (zh) * 2018-10-17 2025-03-21 廖细斌 6-巯基嘌呤核苷类似物
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533191A (ja) 2005-03-21 2008-08-21 ユニバーシティ、カレッジ、カーディフ、コンサルタンツ、リミテッド 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体
JP2014506913A (ja) 2011-03-01 2014-03-20 ニューカナー、バイオメッド、リミテッド がん治療での使用のための５−フルオロ−２’−デオキシウリジンのホスホラミダート誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
WO2015198059A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en) * 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
LT3224268T (lt) * 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
SMT201800303T1 (it) 2015-05-14 2018-07-17 NuCana plc Trattamenti per il cancro
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533191A (ja) 2005-03-21 2008-08-21 ユニバーシティ、カレッジ、カーディフ、コンサルタンツ、リミテッド 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体
JP2014506913A (ja) 2011-03-01 2014-03-20 ニューカナー、バイオメッド、リミテッド がん治療での使用のための５−フルオロ−２’−デオキシウリジンのホスホラミダート誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｃｈｅｍｉｃａｌ Ｃｏｍｍｕｎｉｃａｔｉｏｎ，２０１５年，Ｖｏｌ．５１，Ｎｏ．３８，ｐ．８０７０～８０７３

Also Published As

Publication number Publication date
AU2017273124B2 (en) 2022-09-29
JP2022051965A (ja) 2022-04-01
MA45129A (fr) 2021-05-05
JP2019521971A (ja) 2019-08-08
KR20190011770A (ko) 2019-02-07
KR20220142538A (ko) 2022-10-21
CA3025442C (en) 2024-02-20
AU2017273124A1 (en) 2018-12-13
CA3025442A1 (en) 2017-12-07
BR112018074981A2 (pt) 2019-03-12
GB201609600D0 (en) 2016-07-13
IL263123A (en) 2018-12-31
MY199129A (en) 2023-10-17
WO2017207993A1 (en) 2017-12-07
EP3463384A1 (en) 2019-04-10
SG11201810196RA (en) 2018-12-28
ZA201807811B (en) 2024-05-30
PH12018502491A1 (en) 2019-09-09
IL263123B (en) 2022-09-01
MX2018014840A (es) 2019-03-14
CL2018003443A1 (es) 2019-08-09
CN109562119A (zh) 2019-04-02
EA201892803A1 (ru) 2019-06-28
US20230218655A1 (en) 2023-07-13
US20190374564A1 (en) 2019-12-12
US11400107B2 (en) 2022-08-02
CL2021002669A1 (es) 2022-05-27
EA038030B1 (ru) 2021-06-25

Similar Documents

Publication Publication Date Title
JP7367910B2 (ja) がんの処置
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
AU2014312130B2 (en) Combination therapy for the treatment of glioblastoma
JP2024527087A (ja) スピロノラクトン及びアシルフルベンの組み合わせによるがんの処置
JP6810763B2 (ja) がん治療
HK1261423A1 (en) Cancer treatments
HK1237283A1 (en) Cancer treatments
HK1237283B (en) Cancer treatments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220215

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220322

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220329

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220415

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220419

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231002

R150 Certificate of patent or registration of utility model

Ref document number: 7367910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150